Details for Patent: 10,793,547
✉ Email this page to a colleague
Which drugs does patent 10,793,547 protect, and when does it expire?
Patent 10,793,547 protects TRIKAFTA (COPACKAGED) and is included in two NDAs.
This patent has fifty-one patent family members in thirty-four countries.
Summary for Patent: 10,793,547
| Title: | Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| Abstract: | Compounds of Formula (I): ##STR00001## pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof. |
| Inventor(s): | Abela; Alexander Russell (San Diego, CA), Alcacio; Timothy (San Diego, CA), Anderson; Corey (San Diego, CA), Angell; Paul Timothy (Carlsbad, CA), Baek; Minson (San Diego, CA), Clemens; Jeremy J. (San Diego, CA), Cleveland; Thomas (San Marcos, CA), Ferris; Lori Ann (Wilmington, MA), Grootenhuis; Peter Diederik Jan (Del Mar, CA), Gross; Raymond Stanley (Poway, CA), Gulevich; Anton V. (San Diego, CA), Hadida Ruah; Sara Sabina (La Jolla, CA), Hsia; Clara Kuang-Ju (San Diego, CA), Hughes; Robert M. (San Diego, CA), Joshi; Pramod Virupax (San Diego, CA), Kang; Ping (San Diego, CA), Keshavarz-Shokri; Ali (San Diego, CA), Khatuya; Haripada (San Diego, CA), Krenitsky; Paul John (San Diego, CA), McCartney; Jason (Cardiff by the Sea, CA), Miller; Mark Thomas (San Diego, CA), Paraselli; Prasuna (San Diego, CA), Pierre; Fabrice Jean Denis (La Jolla, CA), Shi; Yi (Natick, MA), Shrestha; Muna (Belmont, MA), Siesel; David Andrew (San Diego, CA), Stavropoulos; Kathy (Quincy, MA), Termin; Andreas P. (Encinitas, CA), Van Goor; Fredrick F. (San Diego, CA), Uy; Johnny (San Diego, CA), Young; Timothy John (San Diego, CA), Zhou; Jinglan (San Diego, CA) |
| Assignee: | Vertex Pharmaceuticals Incorporated (Boston, MA) |
| Application Number: | 15/836,627 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 10,793,547
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULES;ORAL | 217660-001 | Apr 26, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO | ⤷ Sign Up | ||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | GRANULES;ORAL | 217660-002 | Apr 26, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO | ⤷ Sign Up | ||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-002 | Jun 8, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR | ⤷ Sign Up | ||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-001 | Oct 21, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR | ⤷ Sign Up | ||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-001 | Oct 21, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR | ⤷ Sign Up | ||
| Vertex Pharms Inc | TRIKAFTA (COPACKAGED) | elexacaftor, ivacaftor, tezacaftor; ivacaftor | TABLET;ORAL | 212273-001 | Oct 21, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,793,547
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 110346 | ⤷ Sign Up | |||
| Australia | 2017371200 | ⤷ Sign Up | |||
| Australia | 2021211993 | ⤷ Sign Up | |||
| Australia | 2023203944 | ⤷ Sign Up | |||
| Brazil | 112019011626 | ⤷ Sign Up | |||
| Canada | 3046086 | ⤷ Sign Up | |||
| Chile | 2019001553 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
